Although thrombolytic enzymes, such as tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA; also known as urokinase), are available for the treatment of thrombotic disorders, pharmacological interventions using low molecular weight compounds for thrombolytic therapies currently present an unmet medical need. This evidence concerns the gene PLAT and thrombotic disease.